1. Project
  2. PAH-Advance
  3. Organisations

PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).

Full project page

Organisations map overview


Powered by Chris Decubber BV